Tradestie Institutional Equity Comparison Engine · Market Close Jan 07, 2026

FGEN vs AKRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AKRO Captures Overall Composite Edge (60.0 BUY vs 61.2 BUY), While FGEN Leads 3–1 on Growth & Valuation Pillars

AKRO Overall Winner 6-Pillar Tally: FGEN 3 – 1 AKRO (2 Tie) Matrix Metrics: FGEN 5 – 5 AKRO

As of Jan 07, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over FibroGen, Inc (FGEN) on higher Unified Composite conviction (60.0/100 BUY vs. 61.2/100 BUY) after splitting the core matrix 5–5 (led by Profitability & Quality), while FGEN wins 3–1 across the 6-pillar growth and valuation breakdown. FGEN trades at $9.71 (61.4x Forward P/E, -499.1% operating margin) versus AKRO at $54.65 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While FGEN currently prints a higher short-term Unified Composite Score (61.2/100 BUY vs. AKRO 60.0/100 BUY), AKRO captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -499.1% operating margin) and revenue trajectory (+0.0% vs. +774.8% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FGEN vs AKRO
FGEN NASDAQ
FibroGen, Inc
Pharmaceutical Preparations
$9.71
+7.65% 1D
Market Cap $36.5M
TTM Revenue $8.3M
Forward P/E 61.4x
Beta / 30D Vol -20.79β · 102% Vol
Unified Composite Score
61.2 / 100 BUY
Tech 60.0 Fund 56.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 59.2 · SMA20: $8.88 · SMA50: $9.26
AKRO NASDAQ Head-to-Head Winner
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.90β · 2% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 67
RSI-14: 67.3 · SMA20: $54.36 · SMA50: $52.91

6-Pillar Scorecard Institutional Category Breakdown (FGEN 3 – 1 AKRO)

Columns: Metric · FGEN · AKRO
1. Valuation Multiples FGEN
Forward P/E 61.4x N/M
Trailing P/E 61.4x N/M
PEG Ratio N/M N/M
EV / Revenue 4.4x N/M
2. Growth & Scale FGEN
Revenue Growth (YoY) +774.8% +0.0%
Earnings Growth (YoY) +53.6% +0.0%
TTM Revenue (USD) $8.3M N/A
Market Cap $36.5M $4.5B
3. Profitability & Quality AKRO
Gross Margin N/A N/A
Operating Margin -499.1% 0.0%
Net Profit Margin 2598.9% 0.0%
Return on Equity (ROE) -1015.8% -34.5%
4. Balance Sheet & Cash Flow FGEN
Cash Generation (TTM) -$58M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage -1015.8% ROE $11.95 Book/Sh · -34.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 7.3% (30th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Pharmaceutical Preparations Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FGEN (5) vs AKRO (5)
Institutional Metric FGEN AKRO Criterion Row Edge
Market Capitalization
Scale
$36.5M $4.5B Larger Scale AKRO
Trailing P/E Ratio
Valuation
61.4x N/M Lower Multiple FGEN
Forward P/E Ratio
Valuation
61.4x N/M Lower Multiple FGEN
Revenue Growth (YoY)
Growth
+774.8% +0.0% Higher Growth FGEN
Operating Margin (TTM)
Profitability
-499.1% 0.0% Higher Margin AKRO
Net Profit Margin
Profitability
2598.9% 0.0% Higher Margin FGEN
Return on Equity (ROE)
Capital Efficiency
-1015.8% -34.5% Higher ROE AKRO
52-Week Range Position
Momentum
44% ($0–$22) 90% ($21–$58) Stronger Trend AKRO
Beta / 30D Volatility
Risk Regime
-20.79β · 102% Vol 0.90β · 2% Vol Lower Realized Risk AKRO
Unified Institutional Score
Composite Signal
61.2 / 100 (BUY) 60.0 / 100 (BUY) Higher Composite FGEN
Trailing 12M Revenue (USD)
Operating Scale
$8.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$58M EBITDA (-1015.8% ROE) N/A ($11.95 Book/Sh · -34.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AKRO +25.37 pp
FGEN: -24.0% · AKRO: +1.37%
3M Horizon AKRO +49.66 pp
FGEN: -27.18% · AKRO: +22.48%
6M Horizon FGEN +2516.7 pp
FGEN: +2516.59% · AKRO: -0.11%
1Y Horizon AKRO +132.25 pp
FGEN: -38.73% · AKRO: +93.52%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FGEN vs AKRO. Trailing 12-month operating profitability (FGEN -499.1% vs AKRO 0.0%) and valuation multiples (FGEN 61.4x vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

FGEN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$8.3M
Gross MarginN/A
Op. Margin-499.1%
ROE / Fwd P/E-1015.8% · 61.4x
AKRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FGEN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AKRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 7.3%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FGEN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $36.5M market capitalization and -499.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AKRO Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FGEN vs AKRO Key Questions & Quantitative Answers

As of Jan 07, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over FibroGen, Inc (FGEN) on higher Unified Composite conviction (60.0/100 BUY vs. 61.2/100 BUY) after splitting the core matrix 5–5 (led by Profitability & Quality), while FGEN wins 3–1 across the 6-pillar growth and valuation breakdown. FGEN trades at $9.71 (61.4x Forward P/E, -499.1% operating margin) versus AKRO at $54.65 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While FGEN currently prints a higher short-term Unified Composite Score (61.2/100 BUY vs. AKRO 60.0/100 BUY), AKRO captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -499.1% operating margin) and revenue trajectory (+0.0% vs. +774.8% YoY).

FGEN leads the Growth & Scale pillar: FGEN posts +774.8% YoY revenue growth and +53.6% YoY earnings growth on $8.3M TTM revenue (N/A gross margin, -499.1% operating margin), compared with AKRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, FGEN generates $8.3M in USD-normalized revenue versus N/A for AKRO. In operating R&D and SG&A reinvestment, FGEN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKRO.

FGEN screens cheaper on headline valuation multiples. FGEN trades at 61.4x Forward P/E, 61.4x Trailing P/E, N/M PEG, and 4.4x EV/Revenue (unreported EBITDA margin), whereas AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FGEN (-1015.8% ROE) versus AKRO (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, FGEN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-20.79β · 102% Vol realized risk). By comparison, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Jan 07, 2026. For educational research only; not investment advice.